2023年11月13日 · WATERTOWN, Mass. and GAITHERSBURG, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc ...

2023年10月31日 · Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune ...

2020年12月16日 · In this article, we look at what those funds think of Selecta Biosciences, Inc. (NASDAQ:SELB) based on that data.

2022年7月28日 · Selecta Biosciences, Inc. (SELB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

2020年11月20日 · The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.

2023年3月2日 · Selecta Biosciences, Inc. (SELB) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.

2023年3月21日 · Selecta Biosciences Inc (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (OTC: BIOVF) announced topline results from the Phase 3 DISSOLVE I & II trials of SEL-212 in adult patients with chronic ...

2023年3月27日 · Most readers would already be aware that Selecta Biosciences' (NASDAQ:SELB) stock increased significantly by 48% over the past three months.

2023年8月17日 · Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 46.98%, respectively, for the quarter ended June 2023.

2020年10月27日 · In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.